Abstract library

79 results for "caregiver burden".
#1276 Caregivers’ Burden of Patients with Neuroendocrine Tumor and Related Factors
Introduction: Rare and increasing rapidly,patients with NETs have got more and more attention.With so many unknown and the long course of the disease, the caregaviers should bear a long and huge burden.However, the relative reviews are rare.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Liyan Zhang
Authors: Zhang L
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements
Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Keywords: PET burden
#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#2090 Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof.Dr.Dr. Eva Caroline Winkler
#259 Risk of Cardiovascular Events (CV) in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NETs are malignant neoplasms capable of systemic hormone production. Oversecretion of hormones can result in many different symptoms, including CV events such as CAD, valvular disease and stroke.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Chen C C, Liu Z M, Hess G P, Yao J C, ...
#809 Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors
Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Authors: Zhang C, Han X, Tang M, Ji Y, ...
Keywords: CgA NF-PNETs LM
#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#2040 Hepatic Tumor Burden Can Be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)
Introduction: The main tumor burden of patients with neuroendocrine tumor liver metastasis is comprised by hepatic lesions.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Yiming Liu
Authors: Liu Y, Wang Y, Lian F, Shen L, ...